This content is not meant to replace a conversation with a healthcare provider. A healthcare provider can evaluate your symptoms and make the appropriate clinical decisions.
Current Management Approaches for HAE
The World Allergy Organization’s guidelines state that the treat-to-target goal of HAE treatment should be
“achieving complete disease control and sustained improvement in health-related quality of life.”
Current HAE Management
Current HAE Management
There are two ways to manage HAE: by preventing attacks and by treating attacks when they occur. At the moment, there are various medications available, all targeting different stages in the multiple biological pathways that can lead to the formation of bradykinin.
Plasma kallikrein inhibitors
can interrupt the kallikrein-kinin system’s upstream production of bradykinin.
B2 receptor antagonists
actively prevent bradykinin from binding to the B2 receptors that signal blood vessels to become porous and start the release of fluid that results in swelling.
C1-inhibitor infusions
supplement the body’s ability to regulate bradykinin production with functioning
C1-INH proteins.
All of the currently available management options, unfortunately, can force compromises between effectiveness, side effects, and convenience.
Do you feel in control of your HAE, or is it the other way around?
Managing HAE often means either taking a long-term preventative treatment or taking an on-demand treatment when an attack happens. Unfortunately, due to the trade-offs, both of these approaches currently can mean HAE is still in control.
Are you controlling your HAE, or is it the other way around?
Real person living with HAE.
C1-INH, C1-inhibitor; HAE, hereditary angioedema.
Talking HAE management with your doctor.
